Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the presence of autoantibodies directed against complexes of plasma proteins and negatively charged phospholipids (antiphospholipid antibodies—aPL) in particular lupus anticoagulant (LA), anticardiolipin (aCL), and anti-ß2-glycoprotein I (aß2GPI) antibodies, and clinical manifestations such as venous, arterial or microvascular thrombosis, and/or obstetric complications [1–5]. Here, FASLG is linked to autoimmune polyendocrinopathy.